WO2007052238A8 - Chimeric antigens and vaccines - Google Patents

Chimeric antigens and vaccines

Info

Publication number
WO2007052238A8
WO2007052238A8 PCT/IB2006/054143 IB2006054143W WO2007052238A8 WO 2007052238 A8 WO2007052238 A8 WO 2007052238A8 IB 2006054143 W IB2006054143 W IB 2006054143W WO 2007052238 A8 WO2007052238 A8 WO 2007052238A8
Authority
WO
WIPO (PCT)
Prior art keywords
chimeric antigen
disease
orbivirus
polypeptide
subject
Prior art date
Application number
PCT/IB2006/054143
Other languages
French (fr)
Other versions
WO2007052238A2 (en
WO2007052238A3 (en
Inventor
Henk Huismans
Francois Maree
Original Assignee
Univ Pretoria
Henk Huismans
Francois Maree
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pretoria, Henk Huismans, Francois Maree filed Critical Univ Pretoria
Priority to EP06821354A priority Critical patent/EP1951876A2/en
Publication of WO2007052238A2 publication Critical patent/WO2007052238A2/en
Publication of WO2007052238A8 publication Critical patent/WO2007052238A8/en
Publication of WO2007052238A3 publication Critical patent/WO2007052238A3/en
Priority to TNP2008000184A priority patent/TNSN08184A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/135—Foot- and mouth-disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12111—Orbivirus, e.g. bluetongue virus
    • C12N2720/12122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12111—Orbivirus, e.g. bluetongue virus
    • C12N2720/12134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

The invention provides a chimeric antigen which includes an orbivirus VP7 polypeptide with a foreign peptide inserted into a top domain region of said orbivirus VP7 polypeptide. The chimeric antigen in accordance may be used for treating or preventing a disease such as foot and mouth disease, African horsesickness, or bluetongue disease. The invention also extends to a method of inducing an immune response in a subject by administering an effective amount of an immunogenic composition comprising the chimeric antigen and a pharmaceutically acceptable carrier or diluent to the subject thereby to elicit or induce said immune response.
PCT/IB2006/054143 2005-11-07 2006-11-07 Chimeric antigens and vaccines WO2007052238A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP06821354A EP1951876A2 (en) 2005-11-07 2006-11-07 Chimeric antigens and vaccines
TNP2008000184A TNSN08184A1 (en) 2005-11-07 2008-04-24 Chimeric antigens and vaccines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA2005/08983 2005-11-07
ZA200508983 2005-11-07

Publications (3)

Publication Number Publication Date
WO2007052238A2 WO2007052238A2 (en) 2007-05-10
WO2007052238A8 true WO2007052238A8 (en) 2007-06-21
WO2007052238A3 WO2007052238A3 (en) 2007-11-15

Family

ID=38006277

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/054143 WO2007052238A2 (en) 2005-11-07 2006-11-07 Chimeric antigens and vaccines

Country Status (5)

Country Link
EP (1) EP1951876A2 (en)
MA (1) MA29978B1 (en)
TN (1) TNSN08184A1 (en)
WO (1) WO2007052238A2 (en)
ZA (1) ZA200803664B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2311423B1 (en) * 2007-07-27 2010-01-07 Inmunologia Y Genetica Aplicada, S.A. DOUBLE RECOGNITION IMMUNO TEST FOR ANTIBODY DETECTION.
CN103826657A (en) 2011-04-04 2014-05-28 衣阿华大学研究基金会 Methods of improving vaccine immunogenicity
CN106749557B (en) * 2016-12-06 2020-02-11 东北农业大学 Specific antigen epitope polypeptide of bluetongue virus VP7 protein group and application thereof
CN116041447A (en) * 2022-12-29 2023-05-02 北京亿森宝生物科技有限公司 Kit for detecting African horse sickness virus and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0515235A3 (en) * 1991-05-23 1993-03-31 Natural Environment Research Council Dna sequences coding for protein components of african horsesickness virus

Also Published As

Publication number Publication date
MA29978B1 (en) 2008-11-03
EP1951876A2 (en) 2008-08-06
TNSN08184A1 (en) 2009-10-30
ZA200803664B (en) 2009-02-25
WO2007052238A2 (en) 2007-05-10
WO2007052238A3 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
WO2006036550A3 (en) Listeria-based and llo-based vaccines
WO2006126981A3 (en) Compositions and methods for mucosal vaccination
WO2007022151A3 (en) Immunization of avians by administration of non-replicating vectored vaccines
WO2006081007A3 (en) Use of flagellin in tumor immunotherapy
WO2005120565A3 (en) Sars vaccines and methods to produce highly potent antibodies
WO2006113214A3 (en) Vaccine against pandemic strains of influenza viruses
EE200100203A (en) A method of inducing an immune response against a polypeptide antigen and suppressing a cell-associated polypeptide antigen in an animal, a method of treating prostate and breast cancer, and an immunogenic composition.
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
PT2364724E (en) Vaccine compositions comprising a saponin adjuvant
WO2006041933A3 (en) Improved vaccines
WO2008009652A3 (en) Vaccines for malaria
WO2007016185A3 (en) Mono-and bi-functional antibody conjugates as effective adjuvants of protein vaccination
IL184845A0 (en) Chimeric recombinant antigens of toxoplasma gondii
WO2010040000A8 (en) A multicomponent vaccine for malaria providing long-lasting immune responses against plasmodia
WO2009002418A3 (en) T-cell peptide epitopes from carcinoembryonic antigen, immunogenic analogs, and uses thereof
HK1093314A1 (en) Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens
WO2005007673A3 (en) Immunogenic peptides
WO2006007555A3 (en) Rotavirus antigens
WO2007052238A8 (en) Chimeric antigens and vaccines
WO2003000719A3 (en) Multiple antigenic peptide displaying multiple copies of an epitope of plaque-forming polypeptide and methods of using same
WO2006076587A3 (en) Peptides for delivery of mucosal vaccines
EA200702079A1 (en) VACCINE
WO2003083083A3 (en) Methods of using flt3-ligand in immunization protocols
WO2013171661A3 (en) Adjuvant formulations and methods
UA102274C2 (en) Epitope peptid rab6kifl/kif20a and vaccines containing it

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: DZP2008000287

Country of ref document: DZ

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006821354

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2006821354

Country of ref document: EP